SpringerLink
Log in

Bewährtes und Neues in der medikamentösen Epilepsietherapie

Neue Substanzen in bestehende Therapieregime integrieren

  • Fortbildung
  • Published:
Pädiatrie Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price includes VAT (France)

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1

Literatur

  1. Scheffer IE et al. ILAE-Klassifikation der Epilepsien: Positionspapier der ILAE-Kommission für Klassifikation und Terminologie. Z Epileptol. 2018;31(4):296-306

  2. Bast T. Medikamentöse Therapie fokaler Anfälle bei Kindern. Z Epileptol. 2019;32(2):126-34

  3. Lang N et al. Intravenous lacosamide in clinical practice-Results from an independent registry. Seizure. 2016;39:5-9

  4. Strzelczyk A et al. Perampanel in the treatment of focal and idiopathic generalized epilepsies and of status epilepticus. Expert Rev Clin Pharmacol. 2015;8(6):733-40

  5. Schubert-Bast S et al. Postmarketing experience with brivaracetam in the treatment of focal epilepsy in children and adolescents. Epilepsy Behav. 2018;89:89-93

  6. Strzelczyk A, Schubert-Bast S. Expanding the treatment landscape for Lennox-Gastaut Syndrome: current and future strategies. CNS Drugs. 2021;35(1):61-83

  7. Gray RA, Whalley BJ. The proposed mechanisms of action of CBD in epilepsy. Epileptic Disord. 2020;22(S1):10-5

  8. Strzelczyk A et al. Anticonvulsant agents: cannabidiol and fenfluramine. In: Riederer P et al. (Hrsg.) NeuroPsychopharmacotherapy. Cham: Springer International Publishing; 2020. S.: 1-15

  9. www.medicines.org.uk/emc/product/11998/smpc

  10. Strzelczyk A et al. Efficacy, tolerability, and retention of fenfluramine for the treatment of seizures in patients with Dravet syndrome: Compassionate use program in Germany. Epilepsia. 2021;62(10):2518-27

Download references

Author information

Authors and Affiliations

  1. Klinik für Kinder- und ­Jugendmedizin und ­Epilepsiezentrum Frankfurt Rhein-Main, Universitätsklinikum Frankfurt, Theodor-Stern-Kai 7, 60590, Frankfurt am Main, Germany

    Susanne Schubert-Bast

Authors
  1. Susanne Schubert-Bast
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Susanne Schubert-Bast.

Ethics declarations

Die Autorin gibt an, Berater- und Vortragshonorare von UCB Pharma, Eisai, Desitin Arzneimittel, Marinus, Zogenix, GW Pharma, Jazz Pharmaceuticals und Takeda erhalten zu haben.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Schubert-Bast, S. Bewährtes und Neues in der medikamentösen Epilepsietherapie. Pädiatrie 35, 30–33 (2023). https://doi.org/10.1007/s15014-023-4827-9

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s15014-023-4827-9

Search

Navigation